Disclosed positions
| Arcus Biosciences Inc. | RCUS | COM | $968,825,351 | 31,424,760 | SH | None |
| Lakefront Biotherapeutics | LKFT | SPON ADR | $500,157,715 | 16,707,477 | SH | None |
| Assembly Biosciences Inc. | ASMB | COM NEW | $136,770,406 | 4,977,089 | SH | None |
| Kyverna Therapeutics Inc. | KYTX | COM | $36,763,720 | 4,126,119 | SH | None |
| Xilio Therapeutics Inc. | XLO | COM | $6,230,727 | 650,389 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.